Assobiotec - English version

28 February 2025

CheckmAb’s Immunotherapy in Collaboration with Boehringer Ingelheim Advances to Next Stage

CheckmAb S.r.l. announced the successful achievement of the second milestone in the collaboration with Boehringer Ingelheim for the development of a monoclonal antibody (mAb) for cancer immunotherapy.

26 February 2025

Arsenale Bioyards Raises $10M to Cut Biomanufacturing Costs by 90% with First-of-its-Kind end-to-end Platform

Arsenale Bioyards, a neo-industrial company fundamentally redefining scalable biomanufacturing, has announced the successful closure of its first $10 million seed financing round. The round was led by Planet A and byFounders with participation from CDP Ventures, Acequia Capital, Plug N Play, Grey Silo Ventures as well as industrial family offices.

30 July 2024

AGC Biologics’ Seattle Site Achieves Successful Multi-Product Inspection by U.S. Food and Drug Administration for Biologics License Applications

CDMO site shares promising outcomes after in Q1 2024 FDA inspections and is now producing two new products for commercial usage in the U.S.

10 May 2024

Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications

Chiesi Farmaceutici S.p.A., an international, research-focused biopharmaceutical group, and Gossamer Bio, a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib.

25 March 2024

Agreement between Bioindustry Park and Federated Innovation @Mind to accelerate the creation of a virtual district in life science

Working together to develop an innovative and competitive healthcare ecosystem, by focusing on digital and healthcare innovation trends, and strengthening the research and internationalisation of the production sector. This is the aim of the collaboration agreement signed by Federated Innovation @MIND and Bioindustry Park Silvano Fumero, reference points for companies in Lombardy and Piedmont operating in the public and private health and Life Sciences sectors.

08 January 2024

Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide

290 patients participate at study centers in Europe, Asia and Latin America. Results from the study are expected in March 2024.

News

CheckmAb’s Immunotherapy in Collaboration with Boehringer Ingelheim Advances to Next Stage

Arsenale Bioyards Raises $10M to Cut Biomanufacturing Costs by 90% with First-of-its-Kind end-to-end Platform

AGC Biologics’ Seattle Site Achieves Successful Multi-Product Inspection by U.S. Food and Drug Administration for Biologics License Applications

Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications

Agreement between Bioindustry Park and Federated Innovation @Mind to accelerate the creation of a virtual district in life science

Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide

Partner

Where to find us